FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]
   Google Scholar   
Citation:
Blood vol 112 (11) abstr 1003
Meeting Instance:
ASH 2008
Year:
2008
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
976  
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
               
Networks:
 
Study
CALGB-50402
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: